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Applying genetics in inflammatory
disease drug discovery
Lasse Folkersen 1,2, lassefolkersen@gmail.com, Shameek Biswas3, Klaus Stensgaard Frederiksen1,
Pernille Keller1, Brian Fox3 and Jan Fleckner1
Recent groundbreaking work in genetics has identified thousands of small-effect genetic variants
throughout the genome that are associated with almost all major diseases. These genome-wide
association studies (GWAS) are often proposed as a source of future medical breakthroughs. However,
with several notable exceptions, the journey from a small-effect genetic variant to a functional drug has
proven arduous, and few examples of actual contributions to drug discovery exist. Here, we discuss novel
approaches of overcoming this hurdle by using instead public genetics resources as a pragmatic guide
alongside existing drug discovery methods. Our aim is to evaluate human genetic confidence as a
rationale for drug target selection.
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The validation of preclinical drug candidates for
diseases relies on data from several methods.
Knockdown animal models, ex vivo studies, in
vitro cell studies, and in vivo tissue samples from
patients all contribute to preclinical evaluation of
the potential of a drug in the treatment of
disease (Table 1). However, a clinical trial is
required to generate the necessary evidence in
humans. As a result of cost and ethical consid-
erations, only drug candidates with the highest
likelihood of effecting disease improvement are
tested in clinical trials. Although there is no
consensus of what this highest likelihood is,
human genetics has been suggested as a fourth
type of evidence of preclinical drug targets that
can be used to examine causality in humans [1].
Notable examples of the value of human
genetics in drug discovery include rare and
common proprotein convertase subtilisin/kexin1176 www.drugdiscoverytoday.com
1359-6446/ 2015 type 9 (PCSK9) variants, for which several drug
candidates are already undergoing phase III
clinical trials to lower low-density lipoprotein
(LDL) levels [2–4]. However, for most genetic-
effect variants, there is little understanding of the
protein or molecule that mediates the effect. For
many GWAS-based discoveries, this deficiency is
attributed to most disease-associated single
nucleotide polymorphisms (SNPs) being non-
coding and intergenic but having regulatory
potential [5,6].
The primary approach in overcoming this
problem is to combine genetic data with mea-
surements of the molecule in vivo in humans; for
example, studying the variation in the levels of a
drug target candidate, such as high-density li-
poprotein (HDL), interleukin (IL)-6, and secretory
phospholipase A2-IIa (sPLA2-IIa) [7–9]. One hy-
pothesis opines that the existence of an SNP that
causes increased levels of a molecule and alsoThe Authors. Published by Elsevier Ltd. This is an open access article unincreases the risk of disease is strong evidence of
the causality of the molecule in disease. Based on
such evidence, IL6 inhibitors are being investi-
gated in clinical trials for the treatment of car-
diovascular disease. Similar studies have
provided new evidence for the causal and
noncausal involvement of LDL and HDL in car-
diovascular disease. SNPs associated with LDL
levels present a higher risk of cardiovascular
disease, whereas SNPs associated with HDL have
no effect on disease. This corresponds well with
the findings that drugs attempting to target HDL
have had little success, whereas LDL modulators
(statins) are among the most efficacious drugs in
the treatment of cardiovascular disease [7].
The combination of genetic data and drug
target levels is termed ‘Mendelian randomiza-
tion’ and aids in determining the causality of
target molecules in a disease [10]. It is essentially
analogous to the clinical trial. Rather thander the CC BY license (http://creativecommons.org/licenses/by/4.0/).
http://dx.doi.org/10.1016/j.drudis.2015.05.012
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TABLE 1
Human genetics compared with other preclinical assessment methods
Method Strength Weakness
Animal models Show causal relations Nonhuman model
Cellular and ex vivo models Show causal relations in human cells Does not capture whole-organism complexity
In vivo expression Observed in humans; whole organism Does not show causality
Human genetics Shows causal relations in humans; whole organism Observational
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uses random genetic variations to alter the
presence of a target molecule. Thus, human
genetics can be considered Nature’s own ran-
domization experiment, albeit with millions of
independent tests.
So, why is this approach not being adopted
widely in drug discovery? One likely answer is
cost. Given the number of samples that is nec-
essary to reach definitive conclusions, such
measurements can be as expensive as a phase II
clinical trial, rendering it unfeasible for use in
applied pretrial drug target research. Another
possible issue is that many genetic targets in-
herently are undruggable per accepted criteria
[11].
Here, we discuss a pragmatic approach to this
problem: reversing the issue and instead ana-
lyzing a candidate pipeline using current genetic
and genomic resources, based on mRNA ex-
pression instead of protein levels. This method
was applied to 14 established drug targets in
inflammatory autoimmune disease and 12 un-
disclosed drug targets developed at Novo Nor-
disk A/S (http://www.novonordisk.com/). Instead
of de facto drug discovery, the ultimate purpose
of this analysis was to prioritize drug targets,
using the choice of indication as a significant
parameter. Given the current high attrition rates
of drug candidates being evaluated in phase II
clinical trials, this method could strengthen the
choice of indication for a given drug target and,
thus, elevate the number of drug targets passing
clinical phase II trials.
Practical implementation scheme
The principal resources in our implementation
were data on the link between an SNP and a
disease and the correlation between an SNP and
target molecule expression. The former were
obtained from publically available GWAS and, for
the latter, we examined the association with
gene expression using expression quantitative
trait loci (eQTL) databases, in which genotypes
and gene expression in relevant tissues are
profiled. These choices enabled us to establish a
complete in silico analysis pipeline, which is
crucial for practical use in a drug company.In total, seven GWAS and six eQTL databases
were used. The P values from the GWAS were
obtained from dbgap [12]. The studies examined
included rheumatoid arthritis (RA) [13], Crohn’s
disease (CD) and ulcerative colitis (UC) [14],
systemic lupus erythematous (SLE) [15,16],
psoriasis (PSO) [17], and type 1 diabetes mellitus
(T1DM) [18], broadly corresponding to the dis-
ease areas that are being focused on for the drug
candidates. The eQTL data were derived from
studies on individual-level expression and ge-
notype data from relevant tissue and cell types,
including intestinal biopsies [19], monocytes and
B cells [20,21] Collectively, the data covered
177 795 patients.
The study setup is illustrated in Fig. 1. First,
SNPs that affect the expression level of the gene
that encodes a drug target or its ligand were
identified. Then, the disease-related risk of the
identified SNPs was evaluated. The detection of
such risk supports the causal involvement of the
gene in that disease. Here, ‘causality’ is presented
as cases in which the genetic modulation of the
mRNA expression level correlates with the risk of
disease, similar to how drug treatments modu-
late the level or signaling of a target to influence
disease severity.
For each drug target ligand, all SNPs within
200 kb of the transcribed regions of the gene
were queried for their association with gene
expression levels in all available eQTL data sets.
This limit was arbitrary but based on earlier
publications, because most effects were ob-
served in this range [22,23]. Drug target
receptors could also be relevant to investigate;
however, in the candidates investigated here,
most had no eQTL effects; therefore, ligands
were chosen as the primary informant. The
association between gene expression and
genotype was calculated using a linear addi-
tive model. If any SNP was associated with
gene expression (eQTL), its disease
association in GWAS was also examined (in-
cluding that of neighboring SNPs in linkage
disequilibrium).
GWA P values were used directly as down-
loaded from each GWAS. P values for eQTL
effects were calculated according to an additivelinear model. The false discovery rates (FDR)
were calculated by rerunning the algorithm on a
random set of genes. This was done 1000 times
on sets of genes of equal size to the test set. As
shown in Fig. 3d,e a variation of the P value
threshold changed the percentage of genes that
have eQTL-SNPs (step 1, left side of figure) and
the percentage of these eQTL-SNPs that have
GWAS effects (step 2, right side of figure). Based
on this, the cutoff was calculated as P = 6e4,
because this resulted in 5% of random genes
with eQTL effects qualifying as potential drug
targets. This calculation served as the basis for all
algorithm conclusions and is summarized in the
scale in Fig. 2c.
Application and discussion
Figure 2 shows the results of applying the human
genetics method to 14 autoimmune drugs that
are currently approved and used in the treat-
ment of disease, as well as 12 drug target can-
didates that are under development. Our
genetics method supported many established
drug candidates for their primary indications; for
example, tumor necrosis factor (TNF) blockers,
tocilizumab (IL6 receptor; IL6R), and abatacept
(cytotoxic T-lymphocyte-associated protein 4;
CTLA4) are recommended for testing in RA, with
strong genetic significance. The strength of the
evidence was estimated using FDRs that were
based on studies of randomly selected genes in
the same analysis pipeline, as described in above
and in Fig. 3.
Tofacitinib (Janus kinase 3; JAK3) and imi-
quimod (Toll-like receptor 7; TLR7) did not
show genetic evidence according to this
method, which is explained by the lack of
transcriptional regulation and sex chromo-
somal location of the target genes, respec-
tively. This is shown in the left column in Fig. 2,
labeled ‘eQTL’, which corresponds to the upper
decision fork in Fig. 1.
Conversely, established drugs, such as beli-
mumab, had an eQTL effect but only a weak
disease association with its main indication, SLE.
Therefore, the results for the 11 drug target
candidates were interpreted as merely guidance
for the indication. If there was any geneticallywww.drugdiscoverytoday.com 1177
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Yes (57%)
No (38%)
No (43%)
RA
Does the gene have SNPs affecting its
expression? (Cis-eQTL)
No positive or negative
answer
Is this SNP also associated with
disease? (GWAS)
Possible causality; test drug in this disease
IBD SLE
No genetic support for efficacy
(62%)
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FIGURE 1
Illustration of the human genetics drug assessment scheme. Numbers in parenthesis indicate the percentage of targets sorted at each step.
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Eregulated transcription (eQTL), the correspond-
ing association in GWA data was prioritized. If no
eQTL could be identified, the drug target was
considered to be intractable with this method.Anti-TNF
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FIGURE 3
Analysis of signal strength from established drug targets and random samplings of genes. In the plots on the left-hand side of each section, each vertical line
shows the range of expression quantitative trait loci (eQTL) P values for a single gene. These P values are calculated from all single nucleotide polymorphisms
(SNPs) within 200 kb of the gene in all available eQTL cell and tissue types. The horizontal dotted line indicates the significance threshold of P < 6e4. The
percentage indicates the fraction of genes that have at least one SNP with a significant eQTL association. In the plots on the right-hand side of each section, each
vertical line shows the range of genome-wide association studies (GWAS) P values for SNPs surrounding a single gene. However, only SNPs that pass the
significance threshold in the left-side eQTL analysis are included. Therefore, a gene is shown only if it had at least one significant eQTL SNP at P < 6e4. P values
from all available autoimmune GWASs are considered. The percentage indicates the fraction of the eQTL-significant genes that also have a GWAS-significant eQTL-
SNP. (a) Ligands for 14 established autoimmune disease drugs, of which eight have eQTL-significant SNPs. Of these, five have GWAS-significant eQTL-SNPs (as
indicated in Fig. 2). (b) Ligands for internal targets, with results as described in Fig. 2. (c) Results from 1000 random 14-gene grabs from all genes. Of these, 65%
have significant eQTL effects, and of these 5.0% have GWAS-associated eQTL SNPs, corresponding to a false discovery rate (FDR) of 5.0%. (d) The effect of reducing
the P value cutoff to 1e4. This not only reduces the number of targets identified, but also corresponds to an FDR of 3.1%, as seen from a random gene grab. (e)
Increasing the P value cutoff to 1e3 corresponds to an FDR of 6.2%.
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Anti-TNF: rs915654
GWAS P = 1, 6e–79 (RA)
eQTL P = 0.00051 (Monocytes)
Abatacept: rs3116513
GWAS P = 3, 6e–14 (RA)
eQTL P = 0.00034 (Monocytes IFN)
Total: 4 SNPs in 1 tissue(s)
Toculizimab: rs7802442
GWAS P = 0.00048 (UC)
eQTL P = 9.2e–05 (Monocytes 2H LPS)
Ustekinumab: rs668998
GWAS P = 0.00017 (RA)
eQTL P = 1.3e–05 (B cells)
Efalizumab: rs2285459
GWAS P = 0.00026 (UC)
eQTL P = 5.8e–12 (Monocytes IFN)
Total: 2 SNPs in 1 tissue(s)
AT AA(major) GG GG AA AG GG CC TC TTTG TTAG AA
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FIGURE 4
Plot of expression levels by single nucleotide polymorphism (SNP) genotype for all marketed drug ligands that pass the P < 6e4 threshold both for expression
quantitative trait loci (eQTL) and genome-wide association studies (GWAS). Each figure presents one eQTL–GWAS pair. Given that the investigation encompasses
multiple SNPs and tissues per drug target, there are two cases where multiple non-linkage disequilibrium (LD) eQTL–GWAS pairs pass the criteria, as indicated for
(b) and (e). The Y-axis indicates mRNA expression level in arbitrary units on a log2 scale. The X-axis indicates genotype, with homozygote risk-allele always shown
to the right. Specific P values for the eQTL association and the GWAS association are noted below each figure, for the SNP in question or a proxy in high LD, as
described in the main text.
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rection of effects. It is important to note that,
because of compensation mechanisms, it is not
inconceivable for eQTL effects to be reversed
relative to their effect on protein [24]. Therefore,
a complete study of directionality should de-
pend on protein-level measurements. For IL6, we
find that a SNP increasing IL6 mRNA expression
also increases risk of disease, thereby supporting
inhibition of IL6R, consistent with the function of
tocilizumab. Similar observations are made for
ustekinumab and efalizumab. For abatacept, one
would expect that increased levels of CTLA4
would cause increased activation of CD80 and
CD86, thereby increasing inflammatory signal
and, consequently, disease risk. However, the
opposite effect is observed at the mRNA level.
Similar remarks can be made for TNF, although
being an A/T variant, a strand flip is perhaps a
simpler explanation. Therefore, without access to
large-scale protein-based Mendelian randomi-
zation studies, we recommend to base decisions
regarding agonism or antagonism on other
study types, preferably including protein-level
measurements.
This points to one chief limitation of this
method, which is that it only uses mRNA levels,
rather than protein levels. Although mRNA and
protein levels are often consistent, and this is
an assumption that is necessary for performing
the presented analysis, there is no guarantee
that the protein levels reflect the mRNA levels
and, therefore, this is a limitation of the anal-
ysis approach. Additionally, the eQTL and
GWAS steps are not performed in the same
individuals, which is a formal requirement for a
study to be termed ‘Mendelian randomization’.
However, this is the compromise for the re-
quirement of a fully in silico process at rea-
sonable expense. Another limitation is that an
eQTL SNP sometimes affects the expression of
multiple genes; therefore, careful consideration
of the SNP and its neighboring SNPs and genes
is important. The method is also limited by the
current availability of eQTL studies, which
might lead to eQTLs that are cell type or
condition specific, being missed. The eQTL data
are central because few GWAS SNPs are coding,
and it is essential to establish a link between
gene and SNP, beyond just proximal location.
However, as new data become available, the
pipeline is updated. We consider all these
limitations to be acceptable trade-offs toward
using the wealth of large-scale genetic data for
drug development.
Likewise, the availability of GWAS data is
crucial. However, rather than a limitation, this
is a future opportunity: currently the largest1180 www.drugdiscoverytoday.comGWAS focus on predisposition to disease. As
detailed well-powered studies of disease-pro-
gression become available, this might shift
focus to the use of genetics in drug discovery.
However, genetic variants are life long and,
therefore, their use might be most relevant for
investigations into primary prevention of dis-
ease, rather than secondary prevention [25].
Another interesting outlook for the future is
the introduction of well-powered rare variant
discovery through large-scale sequencing
efforts. Although conceptually different, sev-
eral examples exist where genes with rare
coding variants for disease association are also
affected by common expression-modulating
variants, such as PCSK9 [4]. We believe that
future innovations in this field will concern the
combination of alternative phenotyping (e.g.,
disease progression), and novel measurements
(rare-variant sequencing). However, here, we
want to raise the point that public data sets
already contain rich information for use in
pragmatic drug-discovery guidance, if not
stand-alone discovery.
Concluding remarks
Here, we have proposed and implemented a
new method to help select drug target can-
didates, based on their relevance to specific
indications. The relevance of a target is
assessed, based on their causal involvement in
disease risk. SNPs that cause overexpression of
specific genes and are associated with in-
creased disease risk render the gene in ques-
tion causal in the disease. Thus, altering ligand-
induced signaling could decrease the disease
risk or severity.
This approach is well founded and consti-
tutes a pragmatic step to enable drug devel-
opment to benefit from the large investments
in genetics that have been made globally in
recent years, both by academia and the
pharmaceutical industry. This simple concept
complements existing drug discovery meth-
ods, such as animal models and in vitro studies,
with disparate advantages and shortcomings.
By increasing the confidence of the relevance
of a target in a disease, we anticipate that
higher-quality drug targets can be selected
for further development, which will be valu-
able if the attrition rate of new drug candi-
dates in clinical proof-of-principle studies
remains high.
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